Highlights Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Delayed Nasdaq Other stock markets 09:04:46 15/05/2024 pm IST			5-day change	1st Jan Change
0.455 ^USD	-0.02%		-6.61%	-30.00%

25/03	Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	MT
25/03	Top Premarket Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Gainers	25/03	MT
North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/03	CI
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22/02	CI
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center	03/01	CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	07/11	CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients	12/23/12	CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma	09/23/09	CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit	27/23/27	CI
Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit	19/23/19	CI
Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting	13/22/13	CI
Salarius Pharmaceuticals Inc. Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting	13/22/13	CI
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas	01/22/01	CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Earnings Flash (SLRX) SALARIUS PHARMACEUTICALS Posts Q3 Loss $-6.41	10/22/10	MT
Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference	27/22/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Highlights

Filters